Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex (MHC) class II molecules are the predominant presenters of exogenous antigens to T helper cells (reviewed in references 21, 77, and 99). These key molecules are cri...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins
Mitchell, P. J., & Tjian, R. (1989) · Science · doi:10.1126/science.2667136 · Cited by 3,114 · cited 4×
“The mode of action of CIITA has been an enigma since its discovery, due to the lack of consensus DNA-binding motifs and its inability to bind W, X, and Y elements.”
BackgroundInfluentialThe myoD Gene Family: Nodal Point During Specification of the Muscle Cell Lineage
Weintraub, H., Davis, R., Tapscott, S., Thayer, M., Krause, M., Benezra, R., Blackwell, T. K., Turner, D., Rupp, R., Hollenberg, S., et al. (1991) · Science · doi:10.1126/science.1846704 · Cited by 1,572
A Class I Antigen, HLA-G, Expressed in Human Trophoblasts
Kovats, S., Main, E. K., Librach, C., Stubblebine, M., Fisher, S. J., & DeMars, R. (1990) · Science · doi:10.1126/science.2326636 · Cited by 1,407 · cited 2×
“CIITA fails to transactivate the HLA-G promoter in extravillous cytotrophoblast cells but does transactivate HLA-A and B promoters (39).”
BackgroundThe MyoD family and myogenesis: Redundancy, networks, and thresholds
Weintraub, H. (1993) · Cell · doi:10.1016/0092-8674(93)90610-3 · Cited by 1,057
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B. (1994) · Science · doi:10.1126/science.8016643 · Cited by 898 · cited 3×
“Human CIITA is encoded on chromosome 16 (119).”
BackgroundSteimle, V (1993) · Cell · doi:10.1016/0092-8674(93)90685-j · Cited by 864
The molecular biology of the CCAAT-binding factor NF-Y
Mantovani, R. (1999) · Gene · doi:10.1016/s0378-1119(99)00368-6 · Cited by 861
Mermod, N., O'Neill, E. A., Kelly, T. J., & Tjian, R. (1989) · Cell · doi:10.1016/0092-8674(89)90108-6 · Cited by 764
Nod1, an Apaf-1-like Activator of Caspase-9 and Nuclear Factor-κB
Inohara, N., Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S., Carrio, R., Merino, J., Liu, D., Ni, J., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.14560 · Cited by 742
Tanaka, M., & Herr, W. (1990) · Cell · doi:10.1016/0092-8674(90)90589-7 · Cited by 635
Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats
Kobe, B., & Deisenhofer, J. (1993) · Nature · doi:10.1038/366751a0 · Cited by 612 · cited 1×
“An example is the RNase inhibitor family, which includes human and pig RNase inhibitor and Schizosaccharomyces pombe rna1p (44, 52, 98).”
BackgroundMHC Class-II Molecules and Autoimmunity
Nepom, G. T., & Erlich, H. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.002425 · Cited by 519
Muhlethaler-Mottet, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2851 · Cited by 507
REGULATION OF MHC CLASS II GENES: Lessons from a Disease
Mach, B., Steimle, V., Martinez-Soria, E., & Reith, W. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.301 · Cited by 486 · cited 1×
“In humans, a congenital lack of both constitutive and inducible class II results in a profound and generally fatal immunodeficiency (type II bare lymphocyte syndrome [BLS]) (7, 29, 45, 61, 67, 75, 112) marked by a significant reduction of CD4(1) T cells.”
BackgroundMasternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M., Steimle, V., & Reith, W. (2000) · Genes & Development · doi:10.1101/gad.14.9.1156 · Cited by 355
Chang, C.-H., Guerder, S., Hong, S.-C., van Ewijk, W., & Flavell, R. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80681-0 · Cited by 350
Steimle, V, Durand, B., Barras, E., Zufferey, M., Hadam, M. R., Mach, B., & Reith, W. (1995) · Genes & Development · doi:10.1101/gad.9.9.1021 · Cited by 338 · cited 1×
“The upstream X1 region is recognized by RFX, a trimeric complex of RFX family members including RFX5, RFXANK (RFX-B), and RFXAP (32, 74, 87, 117).”
BackgroundMiller, D. M., Rahill, B. M., Boss, J. M., Lairmore, M. D., Durbin, J. E., Waldman, J. W., & Sedmak, D. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.675 · Cited by 337 · cited 1×
“Cytomegalovirus, for example, downregulates expression of CIITA by altering the IFN-g signal pathway, thus diminishing the immune stimulatory function of class II MHC (60, 79).”
BackgroundChang, C. H., Fontes, J. D., Peterlin, M., & Flavell, R. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1367 · Cited by 329 · cited 2×
“Many reports have found that placing CIITA in an array of cell types can result in not only the induction of class II MHC promoters but also the expression of cell surface class II MHC proteins (8, 11, 18, 19, 23, 110, 118).”
BackgroundStructural and functional diversity in the leucine-rich repeat family of proteins
Buchanan, S. G. S. C., & Gay, N. J. (1996) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(96)00003-x · Cited by 312 · cited 1×
“While CIITA has fourLRR which conform precisely to the published consensus (15), CIITA also contains a number of LRR-like sequences (some of which only vary from the consensus by a single residue).”
BackgroundMasternak, K., Barras, E., Zufferey, M., Conrad, B., Corthals, G., Aebersold, R., Sanchez, J.-C., Hochstrasser, D. F., Mach, B., & Reith, W. (1998) · Nature Genetics · doi:10.1038/3081 · Cited by 276 · cited 1×
“The upstream X1 region is recognized by RFX, a trimeric complex of RFX family members including RFX5, RFXANK (RFX-B), and RFXAP (32, 74, 87, 117).”
BackgroundClass II transactivator regulates the expression of multiple genes involved in antigen presentation.
Chang, C. H., & Flavell, R. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.765 · Cited by 267 · cited 3×
“Many reports have found that placing CIITA in an array of cell types can result in not only the induction of class II MHC promoters but also the expression of cell surface class II MHC proteins (8, 11, 18, 19, 23, 110, 118).”
BackgroundKanazawa, S., Okamoto, T., & Peterlin, B. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)80159-4 · Cited by 262 · cited 5×
“This difference may be due simply to differential effects of HIV Tat and its mutants on expression of class II MHC in THP-1 and H-9 cells versus COS cells.”
BackgroundInfluentialCoordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter.
Wright, K. L., White, L. C., Kelly, A., Beck, S., Trowsdale, J., & Ting, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.4.1459 · Cited by 234
Self-citationRFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency
Durand, B. (1997) · The EMBO Journal · doi:10.1093/emboj/16.5.1045 · Cited by 227 · cited 1×
“The upstream X1 region is recognized by RFX, a trimeric complex of RFX family members including RFX5, RFXANK (RFX-B), and RFXAP (32, 74, 87, 117).”
BackgroundWEETMAN, A. P. (1999) · Thyroid · doi:10.1089/thy.1999.9.643 · Cited by 217
Gobin, S. J. P., Peijnenburg, A., Keijsers, V., & van den Elsen, P. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80348-9 · Cited by 210
Induction of MHC Class I Expression by the MHC Class II Transactivator CIITA
Martin, B. K., Chin, K.-C., Olsen, J. C., Skinner, C. A., Dey, A., Ozato, K., & Ting, J. P.-Y. (1997) · Immunity · doi:10.1016/s1074-7613(00)80347-7 · Cited by 208 · cited 2×
“CIITA can also upregulate expression of class I MHC genes and beta-2-microglobulin (b2m) through effects at site a in addition to X- and Y-like sequences in the promoters for these genes (40, 72, 104).”
BackgroundSelf-citationZhu, X.-S., Linhoff, M. W., Li, G., Chin, K.-C., Maity, S. N., & Ting, J. P.-Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6051-6061.2000 · Cited by 201
Self-citationZhong, G., Fan, T., & Liu, L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1931 · Cited by 196
Regulation of transcription of MHC class II genes
Boss, J. M. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80166-5 · Cited by 195
Papageorgiou, A. C. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5162 · Cited by 189 · cited 1×
“An example is the RNase inhibitor family, which includes human and pig RNase inhibitor and Schizosaccharomyces pombe rna1p (44, 52, 98).”
BackgroundMonoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription.
Mantovani, R., Pessara, U., Tronche, F., Li, X. Y., Knapp, A. M., Pasquali, J. L., Benoist, C., & Mathis, D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05410.x · Cited by 189
Piskurich, J. F., Linhoff, M. W., Wang, Y., & Ting, J. P.-Y. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.431 · Cited by 187
Self-citationCREB Regulates MHC Class II Expression in a CIITA-Dependent Manner
Moreno, C. S., Beresford, G. W., Louis-Plence, P., Morris, A. C., & Boss, J. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80015-1 · Cited by 184
Lee, Y. J., Han, Y., Lu, H. T., Nguyen, V, Qin, H., Howe, P. H., Hocevar, B. A., Boss, J. M., Ransohoff, R. M., & Benveniste, E. N. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2065 · Cited by 177 · cited 2×
“b, interleukin 1 (IL-1), IL-4, and IL-10, either up- or downregulate CIITA and class II MHC accordingly (18, 23, 42, 57, 88, 89, 92, 107, 119).”
BackgroundRiley, J. L., Westerheide, S. D., Price, J. A., Brown, J. A., & Boss, J. M. (1995) · Immunity · doi:10.1016/1074-7613(95)90033-0 · Cited by 177
Armstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P.-Y., & Ostrand-Rosenberg, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6886 · Cited by 174 · cited 1×
“Other experiments suggest that class II-transfected tumors are more immunogenic than CIITA transfectants due to an ability of class II-transfected tumors to present endogenous antigen whereas CIITA expression also induces Ii, which favors presentation of exogenous antigens (3, 25).”
BackgroundSelf-citationRejection of mouse sarcoma cells after transfection of MHC class II genes.
Ostrand-Rosenberg, S., Thakur, A., & Clements, V (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.10.4068 · Cited by 171 · cited 1×
“The expression of class II MHC and/or costimulatory molecules has shown promise in increasing tumor immunogenicity and tumor rejection (6, 94, 95).”
BackgroundKretsovali, A., Agalioti, T., Spilianakis, C., Tzortzakaki, E., Merika, M., & Papamatheakis, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6777 · Cited by 167
Nagarajan, U. M., Louis-Plence, P., DeSandro, A., Nilsen, R., Bushey, A., & Boss, J. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80016-3 · Cited by 166 · cited 1×
“The upstream X1 region is recognized by RFX, a trimeric complex of RFX family members including RFX5, RFXANK (RFX-B), and RFXAP (32, 74, 87, 117).”
BackgroundMHC class II restricted antigen presentation
Pieters, J. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80164-1 · Cited by 160
Endosomal proteolysis and MHC class II function
Chapman, H. A. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80038-1 · Cited by 160
Silacci, P., Mühlethaler‐Mottet, A., Steimle, V., Reith, W., & Mach, B. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.4.1329 · Cited by 158 · cited 2×
“CIITA expression appears to be a nearly absolute requisite for expression of class II MHC, whether constitutive or inducible (17, 19, 23, 47, 85, 103, 114, 118, 119).”
BackgroundO'Keefe, G. M., Nguyen, V. T., & Benveniste, E. N. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199904)29:04<1275::aid-immu1275>3.0.co;2-t · Cited by 157
Zhou, H., & Glimcher, L. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90034-9 · Cited by 154
Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C., & Ting, J. P. ‐. (1998) · PubMed · Cited by 153
Self-citationChin, K.-C., Mao, C. D., Skinner, C., Riley, J. L., Wright, K. L., Moreno, C. S., Stark, G. R., Boss, J. M., & Tingt, J. P.-Y. (1994) · Immunity · doi:10.1016/1074-7613(94)90039-6 · Cited by 150
Fontes, J. D., Kanazawa, S., Jean, D., & Peterlin, B. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.941 · Cited by 145
Scholl, T., Mahanta, S. K., & Strominger, J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6330 · Cited by 137
Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C., & Ting, J. P.-Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.233 · Cited by 136
Self-citationMaity, S. N., Sinha, S., Ruteshouser, E. C., & Crombrugghe, B. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42041-8 · Cited by 133
TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action
Nandan, D., & Reiner, N. E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1095 · Cited by 129
Targeted inactivation of myogenic factor genes reveals their role during mouse myogenesis: a review
Arnold, H.-H., & Braun, T. W. (1996) · The International Journal of Developmental Biology · doi:10.1387/ijdb.8735947 · Cited by 128 · cited 1×
“This may be similar to gene regulation in muscle development, where the addition of MyoD cannot convert all cells to muscle cells and the lack of MyoD does not ablate all muscle development (4, 113).”
BackgroundThe Crystal Structure of rna1p
Hillig, R. C., Renault, L., Vetter, I. R., Drell, T. L., Wittinghofer, A., & Becker, J. D. (1999) · Molecular Cell · doi:10.1016/s1097-2765(01)80010-1 · Cited by 127
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
Fontes, J. D., Jiang, B., & Peterlin, B. M. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.12.2522 · Cited by 126 · cited 1×
“TFIIB, TAFIIs (30, 32, and 70), and CREB-binding protein (CBP) have all been demonstrated to interact with the acidic domain of CIITA in vitro, in vivo, and in some cases both (35, 36, 54, 68).”
BackgroundAlterations of the mucosal immune system in inflammatory bowel disease
MacDermoit, R. P. (1996) · Journal of Gastroenterology · doi:10.1007/bf02358624 · Cited by 121
Bénichou, B., & Strominger, J. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4285 · Cited by 120 · cited 1×
“In humans, a congenital lack of both constitutive and inducible class II results in a profound and generally fatal immunodeficiency (type II bare lymphocyte syndrome [BLS]) (7, 29, 45, 61, 67, 75, 112) marked by a significant reduction of CD4(1) T cells.”
BackgroundQuantitative control of MHC class II expression by the transactivator CIITA
Otten, L. A., Steimle, V., Bontron, S., & Mach, B. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199802)28:02<473::aid-immu473>3.0.co;2-e · Cited by 119 · cited 1×
“Further, expression of class II MHC is controlled quantitatively by CIITA (96).”
BackgroundMahanta, S. K., Scholl, T., Yang, F.-C., & Strominger, J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6324 · Cited by 115 · cited 1×
“TFIIB, TAFIIs (30, 32, and 70), and CREB-binding protein (CBP) have all been demonstrated to interact with the acidic domain of CIITA in vitro, in vivo, and in some cases both (35, 36, 54, 68).”
BackgroundWojciechowski, W., DeSanctis, J., Skamene, E., & Radzioch, D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.5.2688 · Cited by 110 · cited 1×
“During Mycobacterium bovis BCG infection of murine macrophages, a mycobacterial N gene product diminishes IFN-g-mediated phosphorylation of STAT-1a, thus reducing CIITA and class II MHC expression (140).”
BackgroundThe two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes
Kern, I., Steimle, V., Siegrist, C.-A., & Mach, B. (1995) · International Immunology · doi:10.1093/intimm/7.8.1295 · Cited by 109 · cited 1×
“A number of class II MHC-related genes including genes encoding HLA-DM (H-2M in mice) and invariant chain (Ii), with promoters similar to those for classical class II genes, are also regulated by CIITA (17, 18, 22, 23, 50, 137).”
BackgroundLu, H., Riley, J. L., Babcock, G. T., Huston, M. M., Stark, G. R., Boss, J. M., & Ransohoff, R. M. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1517 · Cited by 106 · cited 1×
“Indeed, it has been shown that negative modulation of class II MHC can occur via posttranscriptional mechanisms as has been observed with IFN-b (62), and posttranslational mechanisms affecting CIITA also occur with TNF-a (42).”
BackgroundBouteiller, P. L. (1999) · Human Reproduction Update · doi:10.1093/humupd/5.3.223 · Cited by 102
Chin, K.-C., Li, G. G.-X., & Ting, J. P.-Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2501 · Cited by 101
Self-citationIFN-γ Regulation of the Type IV Class II Transactivator Promoter in Astrocytes
Dong, Y., Rohn, W. M., & Benveniste, E. N. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4731 · Cited by 101
GTP Binding by Class II Transactivator: Role in Nuclear Import
Harton, J. A., Cressman, D. E., Chin, K.-C., Der, C. J., & -Y. Ting, J. P. (1999) · Science · doi:10.1126/science.285.5432.1402 · Cited by 99 · cited 5×
“In contrast, substitution with related sequences from Ras rescued CIITA function (43).”
BackgroundInfluentialSelf-citationHLA class II transgenic mice as models of human diseases
Taneja, V., & David, C. S. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01307.x · Cited by 97
Roy, E. L., Mühlethaler‐Mottet, A., Davrinche, C., Mach, B., & Davignon, J. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6582-6589.1999 · Cited by 94
Mice lacking the transcription factor CIITA--a second look.
Williams, G. S., Malin, M., Vremec, D., Chang, C. H., Boyd, R., Benoist, C., & Mathis, D. (1998) · International Immunology · doi:10.1093/intimm/10.12.1957 · Cited by 93 · cited 1×
“For example, it has been shown that in CIITA mice, class II MHC(1) dendritic cells are detected in lymph nodes and thymus, although the level is significantly lower than that for control mice (17, 139).”
BackgroundIFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.
Dong, Y., Rohn, W. M., & Benveniste, E. N. (1999) · PubMed · Cited by 89
A Defect in the Nuclear Translocation of CIITA Causes a Form of Type II Bare Lymphocyte Syndrome
Cressman, D. E., Chin, K.-C., Taxman, D. J., & Ting, J. P.-Y. (1999) · Immunity · doi:10.1016/s1074-7613(00)80017-5 · Cited by 87
Self-citationVillard, J., Peretti, M., Masternak, K., Barras, E., Caretti, G., Mantovani, R., & Reith, W. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3364-3376.2000 · Cited by 86
Isolation of a B-cell-specific promoter for the human class II transactivator
Lennon, A., Ottone, C., Rigaud, G., Deaven, L. L., Longmire, J., Fellous, M., Bono, R., & Alcaïde‐Loridan, C. (1997) · Immunogenetics · doi:10.1007/s002510050202 · Cited by 82
Inflammation and Alzheimer disease
Aisen, P. S. S. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815208 · Cited by 81
Gourley, T., Roys, S., Lukacs, N. W., Kunkel, S. L., Flavell, R. A., & Chang, C.-H. (1999) · Immunity · doi:10.1016/s1074-7613(00)80037-0 · Cited by 81 · cited 1×
“However, one study has found some class II and CIITA message by reverse transcriptionPCR (RT-PCR) in activated mouse T cells treated with IL-12 (41).”
BackgroundCIITA activates the expression of MHC class II genes in mouse T cells
Chang, C., Hong, S., Hughes, C. C. W., Janeway, C. A., & Flavell, R. A. (1995) · International Immunology · doi:10.1093/intimm/7.9.1515 · Cited by 74 · cited 1×
“CIITA is expressed in activated human T cells, which express class II MHC, but not in resting or activated mouse T cells, which lack class II MHC (20).”
BackgroundZeleznik‐Le, N. J., Azizkhan, J. C., & Ting, J. P. ‐. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1873 · Cited by 72
Self-citationMora, C., Wong, F. S., Chang, C., & Flavell, R. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4576 · Cited by 72 · cited 1×
“In nonobese diabetic mice it has been shown that the lack of CIITA prevented diabetes despite noticeable pancreatic infiltration (82), whereas class II MHC deficiency alone was insufficient to prevent cytotoxic T-cell-mediated disease pathology in a model of lymphocytic choriomeningitis virusinduced diabetes (55).”
BackgroundBontron, S., Ucla, C., Mach, B., & Steimle, V. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4249 · Cited by 69
Baskar, S., Clements, V. K., Glimcher, L. H., Nabavi, N., & Ostrand‐Rosenberg, S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3821 · Cited by 69 · cited 1×
“The expression of class II MHC and/or costimulatory molecules has shown promise in increasing tumor immunogenicity and tumor rejection (6, 94, 95).”
BackgroundWright, K. L., Chin, K.-C., Linhoff, M. W., Skinner, C., Brown, J. A., Boss, J. M., Stark, G. R., & Ting, J. P. ‐. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6267 · Cited by 68 · cited 2×
“eling) and the ability to activate transcription through its activation domain and protein-protein interactions (132, 141).”
BackgroundSelf-citationItoh-Lindstrom, Y., Piskurich, J. F., Felix, N. J., Wang, Y., Brickey, W. J., Platt, J. L., Koller, B. H., & Ting, J. P. ‐. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.5.2425 · Cited by 67 · cited 1×
“CIITA expression appears to be a nearly absolute requisite for expression of class II MHC, whether constitutive or inducible (17, 19, 23, 47, 85, 103, 114, 118, 119).”
BackgroundSelf-citationItoh-Lindstrom, Y., Piskurich, J. F., Felix, N. J., Wang, Y., Brickey, W. J., Platt, J. L., Koller, B. H., & Ting, J. P. ‐. (1999) · PubMed · Cited by 66
Self-citationJabrane‐Ferrat, N., Fontes, J. D., Boss, J. M., & Peterlin, B. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4683 · Cited by 66 · cited 1×
“A number of factors interacting with the W box have been described, including the RFX complex (26, 48, 120).”
BackgroundInteractions between tobacco mosaic virus and the tobacco N gene
Erickson, F. L., Dinesh-Kumar, S. P., Holzberg, S., Ustach, C. V., Dutton, M., Handley, V., Corr, C., & Baker, B. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0417 · Cited by 66
Brown, A. M., Linhoff, M. W., Stein, B., Wright, K. L., Baldwin, A. S., Basta, P. V., & Ting, J. P.-Y. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.5.2926-2935.1994 · Cited by 62
Self-citationRohn, W. M., Tang, L. P., Dong, Y., & Benveniste, E. N. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.886 · Cited by 61
Riegert, P., Andersen, R. B., Bumstead, N., Döhring, C., Dominguez-Steglich, M. A., Engberg, J., Salomonsen, J., Schmid, M., Schwager, J., Skjødt, K., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1243 · Cited by 60
Invariant chain alters the malignant phenotype of MHC class II+ tumor cells
Clements, V. K., Baskar, S., Armstrong, T. D., & Ostrand‐Rosenberg, S. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.7.2391 · Cited by 59
Tumor Gene Therapy Made Easy: Allogeneic Major Histocompatibility Complex in the C6 Rat Glioma Model
Beutler, A. S., Banck, M. S., Wedekind, D., & Hedrich, H. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950019228 · Cited by 59 · cited 1×
“Many reports have found that placing CIITA in an array of cell types can result in not only the induction of class II MHC promoters but also the expression of cell surface class II MHC proteins (8, 11, 18, 19, 23, 110, 118).”
BackgroundTwo complementation groups account for most cases of inherited MHC class II deficiency
Lisowska‐Grospierre, B., Fondanèche, M., Rols, M., Griscelli, C., & Fischer, A. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.6.953 · Cited by 57 · cited 1×
“In humans, a congenital lack of both constitutive and inducible class II results in a profound and generally fatal immunodeficiency (type II bare lymphocyte syndrome [BLS]) (7, 29, 45, 61, 67, 75, 112) marked by a significant reduction of CD4(1) T cells.”
BackgroundGhosh, N., Piskurich, J. F., Wright, G. M., Hassani, K., Ting, J. P. ‐., & Wright, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32342 · Cited by 55 · cited 1×
“The first 300 bp of promoter III is sufficient for B-cell function and contains two important sequences including a transcription elongation factor 2-like element (38).”
BackgroundSelf-citationNikcevich, K. M., Piskurich, J. F., Hellendall, R. P., Wang, Y., & Ting, J. P. ‐. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00117-4 · Cited by 54
Self-citationSartoris, S., Valle, M. T., Barbaro, A. D. L., Tosi, G., Cestari, T., D’Agostino, A., Megiovanni, A. M., Manca, F., & Accolla, R. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.814 · Cited by 54 · cited 1×
“Many reports have found that placing CIITA in an array of cell types can result in not only the induction of class II MHC promoters but also the expression of cell surface class II MHC proteins (8, 11, 18, 19, 23, 110, 118).”
BackgroundMHC Class II Gene Silencing in Trophoblast Cells Is Caused by Inhibition of CIITA Expression
Morris, A. C., Riley, J. L., Fleming, W., & Boss, J. M. (1998) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1998.tb00423.x · Cited by 52 · cited 1×
“CIITA expression appears to be a nearly absolute requisite for expression of class II MHC, whether constitutive or inducible (17, 19, 23, 47, 85, 103, 114, 118, 119).”
BackgroundTaxman, D. J., Cressman, D. E., & Ting, J. P. ‐. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1410 · Cited by 50
Self-citationMolecular genetics of the Bare lymphocyte syndrome.
Masternak, K., Mühlethaler‐Mottet, A., Villard, J., Peretti, M., & Reith, W. (2000) · PubMed · Cited by 50
Koivisto, P. A., & Rantala, I. S. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199901)187:2<191::aid-path206>3.0.co;2-3 · Cited by 49 · cited 1×
“CIITA is absent in small-cell lung cancer, and transfection of CIITA can restore class II expression (144).”
BackgroundThe class II transactivator CIITA is a transcriptional integrator
Fontes, J. D., Kanazawa, S., Nekrep, N., & Peterlin, B. M. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00232-4 · Cited by 49
Regulation of MHC class II expression in the central nervous system
Collawn, J. F., & Benveniste, E. N. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00228-2 · Cited by 44
Brown, J. A. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.18.4128 · Cited by 44
Rohn, W. M., Tang, L. P., Dong, Y., & Benveniste, E. N. (1999) · PubMed · Cited by 43
Binding and cooperative interactions between two B cell-specific transcriptional coactivators.
Fontes, J. D., Jabrane‐Ferrat, N., TOTH, C. R., & Peterlin, B. M. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2517 · Cited by 43 · cited 1×
“CIITA interactions with the B-cellspecific protein Bob-1 (OcaB) (34) have been described, but the domain involved is unknown.”
BackgroundHLA Polymorphisms and T Cells in Rheumatoid Arthritis
Weyand, C. M., & Goronzy, J. J. (1999) · International Reviews of Immunology · doi:10.3109/08830189909043018 · Cited by 41 · cited 7×
“Interactions between CIITA, RFX, CREB, and NF-Y are likely to be important as suggested by the observation that a C-terminal domain of RFX is required for cooperative binding between RFX and NF-Y (138).”
BackgroundInfluentialLu, Y., Boss, J. M., Hu, S. X., Xu, H., & Blanck, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.7.2495 · Cited by 40
Brown, A., Wright, K. L., & Ting, J. P. ‐. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74318-x · Cited by 40
Self-citationMartin, B. K., Frelinger, J. G., & Ting, J. P. ‐. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6663 · Cited by 39 · cited 2×
“Restoring class II expression to tumor lines by introduction of either the IFN-g gene (97) or the gene for CIITA (73) can improve the immunogenicity of the tumor.”
BackgroundSelf-citationLaufer, T. M., von Herrath, M. G., Grusby, M. J., Oldstone, M. B. A., & Glimcher, L. H. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.2.589 · Cited by 39 · cited 1×
“In nonobese diabetic mice it has been shown that the lack of CIITA prevented diabetes despite noticeable pancreatic infiltration (82), whereas class II MHC deficiency alone was insufficient to prevent cytotoxic T-cell-mediated disease pathology in a model of lymphocytic choriomeningitis virusinduced diabetes (55).”
BackgroundQuan, V. A., Towey, M., Sacks, S. H., & Kelly, A. P. (1999) · Immunogenetics · doi:10.1007/s002510050579 · Cited by 37
Collinge, M., Pardi, R., & Bender, J. R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1589 · Cited by 36
Douhan, J., Lieberson, R., Knoll, J. H. M., Zhou, H., & Glimcher, L. H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.11.1885 · Cited by 34 · cited 1×
“Finally, some invariant-chain and class II MHC isotype-specific expression in in vitro-generated mutant cell lines has been shown to occur in the absence of functional CIITA, which suggests the existence of isotype-specific transacting factors (31, 122, 149).”
BackgroundCollinge, M., Pardi, R., & Bender, J. R. (1998) · PubMed · Cited by 32
Sartoris, S., Tosi, G., Barbaro, A. D. L., Cestari, T., & Accolla, R. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261028 · Cited by 30
Montani, V., Taniguchi, S., Shong, M., Suzuki, K., Ohmori, M., Giuliani, C., Napolitano, G., Saji, M., Fiorentino, B., Reimold, A. M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.1.5673 · Cited by 30
Self-citationHan, Y., Zhou, Z.-H. L., & Ransohoff, R. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1435 · Cited by 28
Yun, S., Gustafsson, K. T., & Fabre, J. W. (1998) · Transplantation · doi:10.1097/00007890-199807150-00016 · Cited by 26 · cited 3×
“Deletion of the acidic domain of CIITA results in a dominant-negative form of the protein (9, 14, 145) and has been touted as a possible vehicle for suppressing class II gene expression in transgenic animals.”
BackgroundHan, Y., Zhou, Z.-H. L., & Ransohoff, R. M. (1999) · PubMed · Cited by 25
WU, Z., Biro, P. A., Mirakian, R. M., HAMMOND, L. J., Curcio, F., Ambesi‐Impiombato, F. S., & Bottazzo, G. F. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00831.x · Cited by 24 · cited 1×
“In autoimmune thyroiditis, potential interactions between CIITA and single-strand binding protein 1, a regulator of thyroid-stimulating hormone gene expression, may contribute to increased class II MHC expression (5, 81), thus allowing thyroid cell antigen presentation to T cells (143).”
BackgroundExon-intron organization of Xenopus MHC class II β chain genes
Kobari, F., Sato, K., Shum, B. P., Tochinai, S., Katagiri, M., Ishibashi, T., Pasquier, L. D., Flajnik, M. F., & Kasahara, M. (1995) · Immunogenetics · doi:10.1007/bf00179399 · Cited by 24
Lefebvre, S., Moreau, P., Dausset, J. B., Carosella, E. D., & Paul, P. (1999) · Placenta · doi:10.1053/plac.1998.0380 · Cited by 23 · cited 1×
“Expression of CIITA can induce class I promoter activity in trophoblast-derived choriocarcinoma cells (58).”
BackgroundLu, Y., Tschickardt, M., Schmidt, B. J., & Blanck, G. (1997) · Immunology and Cell Biology · doi:10.1038/icb.1997.50 · Cited by 23
Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter
Osborne, A. R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.5095 · Cited by 23 · cited 1×
“Loss of the retinoblastoma protein (Rb), a tumor suppressor, has been linked with loss of class II inducibility in retinoblastoma, nonsmall-cell lung carcinoma and bladder carcinoma (63, 65, 93).”
BackgroundSims, T. N., Goes, N. B., Ramassar, V., Urmson, J. R., & Halloran, P. F. (1997) · Transplantation · doi:10.1097/00007890-199712270-00005 · Cited by 23
Sugawara, M., Scholl, T., Ponath, P. D., & Strominger, J. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8438 · Cited by 23
Villard, J., Mühlethaler‐Mottet, A., Bontron, S., Mach, B., & Reith, W. (1999) · International Immunology · doi:10.1093/intimm/11.3.461 · Cited by 22
Class II MHC genes: a model gene regulatory system with great biologic consequences
Ting, J. P.-Y., & Zhu, X.-S. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00233-6 · Cited by 22
Self-citationSantos, A. N. (1998) · International Immunology · doi:10.1093/intimm/10.5.601 · Cited by 19 · cited 1×
“b, interleukin 1 (IL-1), IL-4, and IL-10, either up- or downregulate CIITA and class II MHC accordingly (18, 23, 42, 57, 88, 89, 92, 107, 119).”
BackgroundTai, A., Zhou, G., Chau, K., & Ono, S. J. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00061-9 · Cited by 19 · cited 1×
“Finally, some invariant-chain and class II MHC isotype-specific expression in in vitro-generated mutant cell lines has been shown to occur in the absence of functional CIITA, which suggests the existence of isotype-specific transacting factors (31, 122, 149).”
BackgroundRamassar, V., Goes, N. B., HOBART, M. G., & Halloran, P. F. (1996) · Transplantation · doi:10.1097/00007890-199612270-00038 · Cited by 16 · cited 1×
“CIITA expression appears to be a nearly absolute requisite for expression of class II MHC, whether constitutive or inducible (17, 19, 23, 47, 85, 103, 114, 118, 119).”
BackgroundMHC class II regulation in vivo in the mouse kidney
Sims, T. N., & Halloran, P. F. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00227-0 · Cited by 13 · cited 1×
“In addition to cytokine-regulated class II MHC expression, the in situ expression of CIITA is also tightly linked to class II MHC gene expression (115, 116).”
BackgroundRigaud, G., Andrea, D. L. B., Ramarli, D., et al. (1996) · Human Immunology · doi:10.1016/0198-8859(96)84742-2 · Cited by 12
Tschickardt, M., Lu, Y., Jacim, M., Ussery, G. D., Steimle, V., Mach, B., & Blanck, G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620417 · Cited by 12
Cited by
Dong, Y., & Benveniste, E. N. (2001) · Glia · doi:10.1002/glia.1107 · Cited by 1,293
Genetic Control of MHC Class II Expression
Ting, J. P.-Y., & Trowsdale, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00696-7 · Cited by 584
Self-citationBiological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 490
Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors
Harding, C. V., & Boom, W. H. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2321 · Cited by 435
NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II
Barboric, M., Nissen, R. M., Kanazawa, S., Jabrane-Ferrat, N., & Peterlin, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00314-8 · Cited by 435
Metadata
- Authors
- Harton, J. A., & Ting, J. P.-Y.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-09
- Volume
- 20
- Issue
- 17
- Pages
- 6185-6194
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2129738605
- Cited by
- 217
- References
- 133
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.